Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
Subscribe To Our Newsletter & Stay Updated
